Dean F. Bajorin, MD
Memorial Sloan Kettering Cancer Center
8
3
8
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+6 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Robert J. Motzer, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Harry W. Herr, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Primo N. Lara, MD
University of California, Davis
Shared therapeutic areas:
Worked with same sponsors:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Ciro Gallo, M.D., Ph.D.
University of Campania Luigi Vanvitelli
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
All 8 trials loaded